GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Core Insights - GH Research PLC is a clinical-stage biopharmaceutical company focused on transforming the treatment of psychiatric and neurological disorders [3] - The company will host a conference call on February 3, 2025, to provide updates on the Phase 2b trial of GH001 for treatment-resistant depression (TRD) [1][2] Company Overview - GH Research PLC is dedicated to developing novel therapies for psychiatric and neurological disorders, with a primary focus on mebufotenin for TRD [3] - The lead product candidate, GH001, utilizes a proprietary inhalation method for administration [4] Clinical Trial Insights - In the completed Phase 1/2 trial (GH001-TRD-102), 87.5% of patients with TRD achieved ultra-rapid remission with the individualized single-day dosing regimen [4]